Galapagos raises $300M on the back of first PhIII filgotinib success; Incyte pushes into PhIII with topical Jakafi
→ Galapagos $GLPG wasn’t about to let the success of its first Phase III for filgotinib — handled by lead partner Gilead — go by without a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
